Kilitch Drugs (India) Ltd Share Price

Pharmaceuticals - Indian - Formulations

NSE: KILITCH Small Cap ISIN: INE729D01010

As on 31 January 2025 at 13:59 IST

₹313.95

-0.15

(-0.05%)

Sell Buy

Over 1 Month

-1.06%

Over 6 Months

-11.36%

Over 1 Year

-29%

Over 3 Years

40.16%

Kilitch Drugs (India) Ltd Summary

Close ₹ 313.95

Open ₹ 315.80

High ₹ 318.35

Low ₹ 310

Volume 3,054

Net Turnover (in ₹ Cr) ₹ 0.33

52Wk High ₹ 470

52Wk Low ₹ 300

52Wk High / Low

300

470

Kilitch Drugs (India) Ltd Fundamentals

Key Financial Data

Market Cap (in ₹Cr) ₹ 505.15

EPS (TTM) 13.71

Book Value (BV) 147.27

Div. Yield -

P/E (TTM) 22.73

Price/Book Value 2.12

Delivery % 86.45 %

Face Value 10

Key Ratios

PE Ratio 35.67

PB Ratio 2.81

EV to Sales 4.86

PEG Ratio 4.28

ROA 6.91

ROE 8.39

Debt-Equity 0.13

Net Profit Margin 13.35

Operating Profit Margin 20.23

Kilitch Drugs (India) Ltd Financials

Profit and Loss

Consolidated

Standalone

Yearly

Quarterly

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	158.85	142.52	117.14	71.19	57.45
Total Expenses	139.50	130.50	107.53	66.07	55.84
Profit Before Tax	19.35	12.01	9.61	5.12	1.61
Profit After Tax	13.58	8.28	6.21	3.77	0.84
Operating Profit after Depreciation	25.28	16.93	10.81	5.87	2.32

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	61.98	64.22	64.54	29.96	31.53
Total Non Current Assets	94.07	93.12	95.74	122.81	87.05
Total Current Assets	145.99	126.40	114.10	80.36	55.79
TOTAL ASSETS	240.06	219.52	209.85	203.18	142.83
Total Shareholder's Fund	176.29	151.60	139.09	127.13	118.25

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	-0.15	2.59	5.78	45.66	4.46
Net Cash used in Investing Activities	-9.54	7.92	-15.25	-37.57	-10.45
Net Cash used in Financing Activities	8.81	-0.72	7.03	1.61	0.85

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	137.79	122.38	109.72	74.21	66.48
Total Expenses	114.43	102.93	95.79	66.70	61.25
Profit Before Tax	23.35	19.45	13.93	7.51	5.22
Profit After Tax	17.57	15.72	10.53	6.16	4.46
Operating Profit after Depreciation	25.26	20.43	14.59	8.26	5.94

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	15.70	15.08	14.18	6.94	7.67
Total Non Current Assets	145.98	137.65	134.57	124.09	118.09
Total Current Assets	141.49	114.77	97.72	71.76	56.02
TOTAL ASSETS	287.47	252.42	232.29	195.85	174.11
Total Shareholder's Fund	222.92	195.93	178.03	162.93	151.65

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	-11.19	6.10	5.21	6.13	7.29
Net Cash used in Investing Activities	-10.10	6.24	-16.08	-5.35	-10.08
Net Cash used in Financing Activities	11.40	3.04	7.55	2.27	1.44

Particulars (in ₹ Cr.)	2024-09	2024-06	2024-03	2023-12	2023-09
Total Revenue	47.47	33.45	44.82	31.79	41.20
Total Expenses	41.38	31.79	37.74	29.52	32.58
Profit Before Tax	10.33	1.65	5.30	2.82	6.78
Profit After Tax	8.61	0.11	3.68	1.74	5.09
Operating Profit after Depreciation	11.25	4.23	7.55	5.23	9.11

Particulars (in ₹ Cr.)	2024-09	2024-06	2024-03	2023-12	2023-09
Total Revenue	45.35	33.42	39.14	29.77	31.57
Total Expenses	39.76	30.20	33.92	25.74	25.73
Profit Before Tax	10.58	5.59	5.27	6.60	5.93
Profit After Tax	8.85	4.05	3.64	5.50	4.24
Operating Profit after Depreciation	11.40	6.43	6.12	7.43	6.76

Kilitch Drugs (India) Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3

S1 308.15

S2 302.20

S3 293.40

Pivot 316.95

R1 322.90

R2 331.70

R3 337.65

Moving Average

20 SMA 333.56

50 SMA 326.58

100 SMA 331.89

200 SMA 336.68

Kilitch Drugs (India) Ltd Corporate Actions

Dividend

Bonus

Splits

Rights

AGM

EGM

No available data

AGM Date: 29 Sep 2022

Board of Directors approved unaudited financial results for the quarter ended 30th June, 2022. approved the appointment of Cost Auditor. Approved Notice of 30th Annual General Meeting of the Company and fixed the date of the same. Dear Sir, Please find proceeding of 30th Annual General Meeting of the Companhy As per the requirements of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, the Company had provided remote e-voting and e-voting facility (during AGM) to its members on the business transacted at the 30th Annual General Meeting (AGM) of the Company held on Thursday, 29th September, 2022 at 10:00 A.M. through Video Conferencing (VC)/Other Audio Video Means (OAVM). The Company had appointed M/s. Deep Shukla & Associates, Practicing Company Secretary as the scrutinizer for the remote e-voting and e-voting facility at the AGM. As per the Scrutinizer's Report, all resolutions as set out in the Notice of 30th Annual General Meeting have been duly approved by the members of the Company. Please find attached voting results and the Scrutinizer's Report on voting held through e-voting at the 30th AGM of the Company. (As Per BSE Announcement dated on 30.09.2022)

AGM Date: 29 Sep 2023

Considered and approved financial results for the quarter ended 30th June, 2023 Detail disclosure of Book Closure for the purpose of AGM is hereby enclosed Intimation to Stock Exchanges regarding newspaper publication of AGM notice (As Per BSE Announcement Dated on 04/09/2023) Enclosing the proceeding of the AGM (As Per BSE Announcement dated on 29.09.2023)

AGM Date: 27 Sep 2024

Notice of 32' Annual General Meeting of the Company for the financial year ended 31 March, 2024 to be convened and held on Friday, 27' September, 2024 at 9:30 am through video conferencing and other audio visual means only. We are hereby submitting the Notice of 32nd Annual General Meeting of the Company to be held on 27th September, 2024 (As per BSE Announcement Dated on 02/09/2024) We hereby submit proceeding and outcome of 32nd Annual General meeting of the Company (As per BSE Announcement Dated on 27/09/2024)

EGM Date: 11 Apr 2023

Disclosure pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 We would like to inform you that Extraordinary General Meeting (EGM) of the Company will be held on Tuesday, 11th April, 2023, at 9:00 am (IST) through Video Conferencing or Other Audio Visual Means. (As per BSE Announcement Dated on 18/03/2023) Pursuant to Regulation 30 and 47 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015 ('Listing Regulations'), please find enclosed herewith the copy of Newspaper Publication published on Sunday, 19th March, 2023 in the Free Press Journal - English Edition and Nava Shakti - Marathi Edition pertaining to Notice of Extraordinary General Meeting and e-voting details. (As Per BSE Announcement dated on 20.03.2023) This is to inform you that the Extraordinary General Meeting of the members of Kilitch Drugs (India) Limited was held today i.e. Tuesday, the 11th day of April, 2023 at 9:00 am through Video Conferencing (VC)/ Other Audio Visual Means (OAVM). In this regard, please find enclosed the proceedings as required under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. (As per BSE Announcement Dated on 11/04/2023) As per the requirements of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, the Company had provided remote e-voting and e-voting facility (during EGM) to its members on the business transacted at the Extraordinary General Meeting (EGM) of the Company held on Tuesday, 11th April, 2023 at 9:00 A.M. through Video Conferencing (VC)/Other Audio Video Means (OAVM). The Company had appointed M/s. Deep Shukla & Associates, Practicing Company Secretary as the scrutinizer for conducting the e-voting process. The Scrutinizers' Report and Voting Results is enclosed herewith. (As per BSE Announcement Dated on 12/04/2023)

Kilitch Drugs (India) Ltd Peer Comparison

Company	Price	Market Cap (in ₹ Cr)
Kilitch Drugs (India) Ltd	₹311.65	₹501.21
Sun Pharmaceuticals Industries Ltd	₹1,745.25	₹4,18,743.94
Divis Laboratories Ltd	₹5,733.60	₹1,52,209.07
Cipla Ltd	₹1,458.15	₹1,17,762.24
Torrent Pharmaceuticals Ltd	₹3,357.15	₹1,13,616.11
Mankind Pharma Ltd	₹2,488.40	₹1,02,663.15

Kilitch Drugs (India) Ltd News

Kilitch Drugs (India) announces board meeting date

On 12 November 2024

05 Nov 2024, 01:41 pm

Kilitch Drugs (India) to convene AGM

On 27 September 2024

31 Aug 2024, 03:38 pm

Kilitch Drugs (India) to conduct board meeting

On 8 August 2024

02 Aug 2024, 05:27 pm

Kilitch Drugs (India) to declare Quarterly Result

On 27 May 2024

20 May 2024, 07:21 pm

Kilitch Drugs (India) to conduct board meeting

On 8 February 2024

01 Feb 2024, 07:34 pm

Kilitch Drugs (India) Ltd Stock Analysis

Annual revenue for Kilitch Drugs (India) Ltd increased by 12.59% to ₹137.79 crore in FY 2024 from ₹122.38 crore in FY 2023.
Annual Net Profit for Kilitch Drugs (India) Ltd increased by 11.81% to ₹17.57 crore in FY 2024 from ₹15.72 crore in FY 2023.
Promoter Shareholding in Kilitch Drugs (India) Ltd remains unchanged by 0.00% in the most recent quarter, from 69.23% in September 2024 to 69.23% in December 2024.
Kilitch Drugs (India) Ltd delivered a 1-year return of -29% compared to the Nifty 50, which provided a return of 8.03% as of the last trading session.
Kilitch Drugs (India) Ltd share price moved down by 0.05% from its previous close of INR ₹314.10. The latest Kilitch Drugs (India) Ltd share price is INR ₹313.95.
Kilitch Drugs (India) Ltd share price today has been at a low of 310 and a high of 318.35. Over the past 52 weeks, the Kilitch Drugs (India) Ltd share price has seen a low of 300 and a high of 470.